性做久久久久久坡多野结衣-性做久久久久久久久浪潮-性欲影院-性影院-国产精品线路一线路二-国产精品兄妹在线观看麻豆

青旗(上海)生物技術發展有限公司
中級會員 | 第5年

4006560232

當前位置:青旗(上海)生物技術發展有限公司>>細胞庫>>細胞系>> 人肝癌細胞SNU-475

人肝癌細胞SNU-475

參  考  價面議
具體成交價以合同協議為準

產品型號

品       牌其他品牌

廠商性質生產商

所  在  地上海市

更新時間:2021-05-25 11:12:15瀏覽次數:449次

聯系我時,請告知來自 化工儀器網
同類優質產品更多>
供貨周期 現貨 規格 T25培養瓶x1 1.5ml凍存管x2
貨號 BFN60800682 應用領域 醫療衛生,生物產業
主要用途 僅供科研
青旗(上海)生物技術發展有限公司,總部位于上海浦東新區,依托本地高校資源,逐步發展成為以生物技術為主的研發、生產、培訓為一體的綜合化產業平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫學科研用戶提供更優質的服務!

細胞名稱

人肝癌細SNU-475                  

img1

貨物編碼

BFN60800682

產品規格

T25培養x1

1.5ml凍存x2

細胞數量

1x10^6

1x10^6

保存溫度

37

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途           3類

 

培養體系

DMEM高糖培養基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

培養溫度

37

二氧化碳濃度

5%

簡介

人肝癌細SNU-475取自亞洲人,男性。人肝癌細SNU-475由青旗(上海)生物技術發展有限公司2018年引種ATCC(CRL-2236)

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: Seoul National University (SNU) cell line collection.

Characteristics: Has lost chromosome Y.

Doubling time: 66 hours (PubMed=7543080).

Microsatellite instability: Stable (MSS) (Sanger).

Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

STR信息

Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 8,11

D16S539: 12

D5S818: 10,13

D7S820: 7,12

TH01: 7,9

TPOX: 8,9

vWA: 14

參考文獻

PubMed=7543080; DOI=10.1002/ijc.2910620308

Park J.-G., Lee J.-H., Kang M.-S., Park K.-J., Jeon Y.-M., Lee H.-J., Kwon H.-S., Park H.-S., Yeo K.-S., Lee K.-U., Kim S.-T., Chung J.-K., Hwang Y.-J., Lee H.-S., Kim C.Y., Lee Y.I., Chen T.-R., Hay R.J., Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Characterization of cell lines established from human hepatocellular carcinoma.

Int. J. Cancer 62:276-282(1995)

 

PubMed=8824565; DOI=10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X

Kang M.-S., Lee H.-J., Lee J.-H., Ku J.-L., Lee K.P., Kelley M.J., Won Y.-J., Kim S.-T., Park J.-G.

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Int. J. Cancer 67:898-902(1996)

 

PubMed=19956504; DOI=10.4143/crt.2005.37.1.1

Ku J.-L., Park J.-G.

Biology of SNU cell lines.

Cancer Res. Treat. 37:1-19(2005)

 

PubMed=16616112; DOI=10.1016/j.cancergencyto.2005.08.022

Park S.-J., Jeong S.-Y., Kim H.J.

Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.

Cancer Genet. Cytogenet. 166:56-64(2006)

 

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

 

PubMed=23887712; DOI=10.1038/ncomms3218

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218-2218(2013)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

驗收細胞注意事 

1、收到人肝癌細SNU-475細胞,請查看瓶子是否有破裂,培養基是否漏出,是否渾濁,如有請盡快聯系 

2、收到人肝癌細SNU-475細胞,如包裝完好,請在顯微鏡下觀察細胞,由于運輸過程中的問題,細胞培養瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現細胞懸浮的情況,出現此狀態時,請不要打開細胞培養瓶,應立即將培養瓶置于細胞培養箱里靜 3-5 小時左右,讓細胞先穩定下,再于顯微鏡下觀察,此時多數細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理 

3、收到人肝癌細SNU-475細胞后,請鏡下觀察細胞,用恰當方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養瓶中。棄掉原液,使用新鮮配制的培養基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養。若細胞迏 80% ,血清濃度還是 10 

4、收到人肝癌細SNU-475細胞時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養瓶中培養基吸出,留 5-10ML 培養基繼續培養:超 80%匯合度時,請按細胞培養條件傳代培養。如為懸浮細胞,吸出培養液1000 /分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養基懸浮細胞后移回培養瓶 

5、將培養瓶置 37培養箱中培養,蓋子微微擰松。吸出的培養基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需 

624 小時后,人肝癌細SNU-475細胞形態已恢復并貼滿瓶壁,即可傳代。(貼壁細胞)將培養瓶里的培養基倒去, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準,一 1-3 分鐘,不超 5 分鐘。可以放37培養箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內離心1000rpm/5min。棄上清,視細胞數量決定分瓶數,一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經驗為準。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可 

7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養瓶和換新鮮的培養液375%CO2 培養。

 

特別提醒 原瓶中培養基不宜繼續使用,請更換新鮮培養基培養。

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~
撥打電話
在線留言
主站蜘蛛池模板: 百色市| 武平县| 南川市| 瑞昌市| 无极县| 饶平县| 班玛县| 漳平市| 杂多县| 炎陵县| 隆安县| 大庆市| 台南县| 蒲城县| 融水| 威远县| 兰考县| 健康| 绥滨县| 云南省| 通化市| 寻乌县| 东乡县| 天门市| 马尔康县| 涿州市| 宁蒗| 威远县| 河西区| 峨眉山市| 连云港市| 友谊县| 区。| 扎兰屯市| 江达县| 沿河| 大关县| 肥城市| 林芝县| 汝南县| 抚州市|